Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Medtronic. The associated price target remains the same with $100.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Travis Steed has given his Buy rating due to a combination of factors that suggest a positive outlook for Medtronic. Despite a slightly lower-than-expected revenue growth in the first quarter, the announcement of Elliott Management’s investment in Medtronic is seen as a favorable development. This investment, combined with the appointment of new independent directors, is expected to drive strategic changes and potentially accelerate Medtronic’s ongoing turnaround efforts.
Medtronic’s challenges in certain business areas, such as neurovascular and pelvic health, are anticipated to improve in the coming years. The company is addressing these issues with new product launches and organizational changes, which are expected to enhance performance. Furthermore, the alignment between Medtronic and Elliott Management is viewed as a positive step towards achieving long-term growth, supported by Elliott’s successful track record in the healthcare sector.
In another report released today, Barclays also reiterated a Buy rating on the stock with a $109.00 price target.